Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Tests moderate exercise training in people with hypertrophic cardiomyopathy

Tests a moderate exercise program against usual activity in adults with hypertrophic cardiomyopathy.

Plain-language title generated from the registry record
Registry title: Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

Key facts

Where
San Francisco, United StatesSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT05818605, who can take part

Where in United States

  • University of California San FranciscoSan Francisco, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of California, San Francisco
Trial code
NCT05818605
Record updated
20 November 2025
Original description
The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and cardiac function. About 70 participants will be recruited and randomized on a 1:1 ratio to either moderate intensity training or usual physicial activity interventions. Patients will be followed during a period of 24 weeks and assesesments as physical examination, questionnaires, 12 lead ecg's, biomarker levels, echocardiogram, Cardiac Magnetic resonance, PET and CPET will be performed to evaluate their response to the intervention.Read full original descriptionShow less

The EXerCise traIning To rEcovery in HCM Trial

The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and cardiac function. About 70 participants will be recruited and randomized on a 1:1 ratio to either moderate intensity training or usual physicial activity interventions. Patients will be followed during a period of 24 weeks and assesesments as physical examination, questionnaires, 12 lead ecg's, biomarker levels, echocardiogram, Cardiac Magnetic resonance, PET and CPET will be performed to evaluate their response to the intervention.

Inclusion: Patients 18 to 80 years of age with diagnosis of hypertrophic cardiomyopathy1 defined by left ventricular hypertrophy with end-diastolic wall thickness 15 mm or greater on 2D echocardiography in the absence of other primary causes of left ventricular hypertrophy or wall thickness between 13 and 15 mm in the presence of other features suggestive of hypertrophic cardiomyopathy, such as systolic anterior motion of the mitral valve leaflets, family history of hypertrophic cardiomyopathy, or positive genetic test result; Left ventricular outflow tract gradient <30 mmHg at rest and with provocation; Left ventricular ejection fraction ≥ 50% by biplane Simpson's method; Access to exercise equipment at home or at a fitness center; Ability to complete study related testing including online surveys and smart phone use; Ability to perform 24 weeks of exercise training.

Exclusion: LVOT obstruction being evaluated for septal reduction therapy; less than 3 months after; History of ICD placement in the previous 3 months; Clinical decompensation in the previous 3 months, defined as New York Heart Association class IV congestive heart failure symptoms or Canadian Cardiovascular Society class IV angina symptoms; History of exercise-induced syncope or ventricular arrhythmias; History of septal reduction therapy - surgery or ablation; History of hypotensive response with exercise testing (>20 mm Hg decrease of systolic blood pressure from baseline blood pressure or an initial increase in systolic blood pressure followed by a decrease of systolic blood pressure >20 mm Hg); Left ventricular ejection fraction less than 50% by echocardiography; Life expectancy less than 12 months; Pregnant or planned pregnancy; Inability to exercise owing to any medical or other limitations; Unwillingness to refrain from competitive sports, burst activity, or heavy isometric exercise for the duration of the study, if assigned to the non-exercise group.

ClinicalTrials.gov NCT05818605